Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunosuppression without prophylactic antilymphocyte preparations.

W W Pfaff1, P R Patton, R J Howard

  • 1Department of Surgery, University of Florida College of Medicine, Gainesville.

Clinical Transplants
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The efficacy and safety of a pharmacologic protocol for maintaining coronary artery bypass patients at a higher mean arterial pressure during cardiopulmonary bypass. 1998.

The journal of extra-corporeal technology·2013
Same author

Pre-transplant myeloid dendritic cell deficiency associated with cytomegalovirus infection and death after kidney transplantation.

Transplant infectious disease : an official journal of the Transplantation Society·2012
Same author

The risk of comorbidity.

Annals of the rheumatic diseases·2012
Same author

Blood transfusions in organ transplant patients: mechanisms of sensitization and implications for prevention.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2011
Same author

Whipple's Disease: Its Relationship to the Rheumatic State.

Transactions of the American Clinical and Climatological Association·2011
Same author

Pulmonary calcification and sensitivity to histoplasmin, tuberculin and haplosporangin.

Journal of the American Medical Association·2010
Same journal

Clinical Relevance of Donor-Specific IgM Antibodies in HLA Incompatible Renal Transplantation: A Retrospective Single-Center Study.

Clinical transplants·2017
Same journal

Influenza Immunization and the Generation of Anti-HLA and Anti-MICA Antibodies in Patients with Renal Failure and in Kidney Transplant Recipients.

Clinical transplants·2017
Same journal

From Accurate Assessment of Anti-HLA Antibody MFI to Complement-Binding Assays.

Clinical transplants·2017
Same journal

Post-transplant Desensitization for Deceased Donor Kidney Transplant Recipients: A Single Center Experience.

Clinical transplants·2017
Same journal

Acute Rejection in 6-Antigen HLA-Matched Kidney Transplant Recipients: Risk Factors and Outcomes from the Wisconsin Allograft Recipient Database (WisARD).

Clinical transplants·2017
Same journal

C1q Donor-Specific Antibody Associates with Post-transplant Biopsy Findings in Highly- Sensitized Kidney Transplant Recipients.

Clinical transplants·2017
See all related articles

Triple-drug immunosuppression shows promise for graft survival, comparable to other methods. However, older patients and Black recipients face higher risks, while diabetes and initial graft function impact outcomes.

Area of Science:

  • Nephrology
  • Transplantation Immunology

Background:

  • Optimizing immunosuppression is crucial for long-term graft survival in kidney transplantation.
  • Cyclosporine A (CsA) era protocols have influenced graft outcomes.
  • Understanding recipient factors is key to improving transplant success rates.

Purpose of the Study:

  • To evaluate the efficacy of triple-drug immunosuppression post-transfusion compared to antilymphocyte preparations.
  • To assess the impact of CsA on graft half-life (T1/2) in different donor types.
  • To identify demographic and clinical factors influencing patient and graft survival.

Main Methods:

  • Retrospective analysis of kidney transplant recipients.
  • Comparison of triple-drug immunosuppression with prophylactic antilymphocyte therapy.

Related Experiment Videos

  • Assessment of graft survival, patient survival, and graft half-life (T1/2).

    • Main Results:

    • Triple-drug immunosuppression achieved graft survival comparable to antilymphocyte protocols.
    • Cyclosporine A significantly improved T1/2 for cadaveric and living-related donor grafts.
    • Patients aged 65+ had higher mortality; extreme youth was not a risk factor.
    • Black recipients experienced excessive late graft loss.
    • Diabetic recipients showed minimal decline in survival rates.
    • First and multiple graft recipients had similar transplant survival.
    • Delayed graft function was associated with significant costs within this regimen.

    Conclusions:

    • Triple-drug immunosuppression is a viable alternative to antilymphocyte preparations for kidney transplant recipients.
    • Age and race are significant factors affecting long-term transplant outcomes.
    • While diabetes has a minor impact, delayed graft function remains a critical concern.